CN117153251A - Method and system for screening monitoring sites of lymphoma tiny residual focus - Google Patents
Method and system for screening monitoring sites of lymphoma tiny residual focus Download PDFInfo
- Publication number
- CN117153251A CN117153251A CN202311082157.9A CN202311082157A CN117153251A CN 117153251 A CN117153251 A CN 117153251A CN 202311082157 A CN202311082157 A CN 202311082157A CN 117153251 A CN117153251 A CN 117153251A
- Authority
- CN
- China
- Prior art keywords
- cancer cells
- lymphoma
- division
- residual
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000012216 screening Methods 0.000 title claims abstract description 34
- 238000012544 monitoring process Methods 0.000 title claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 104
- 201000011510 cancer Diseases 0.000 claims abstract description 95
- 208000007660 Residual Neoplasm Diseases 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 13
- 230000032823 cell division Effects 0.000 claims abstract description 9
- 230000003902 lesion Effects 0.000 claims abstract description 7
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 4
- 238000012545 processing Methods 0.000 claims description 21
- 238000004364 calculation method Methods 0.000 claims description 12
- 238000009792 diffusion process Methods 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010586 diagram Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 abstract description 3
- 230000002542 deteriorative effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 89
- 238000001514 detection method Methods 0.000 description 10
- 206010069754 Acquired gene mutation Diseases 0.000 description 7
- 230000037439 somatic mutation Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Abstract
The invention discloses a method and a system for screening monitoring sites of tiny residual focuses of lymphomas, and relates to the technical field of monitoring of the focuses of lymphomas. The method and the system for screening the monitoring sites of the minimal residual lesions of the lymphomas comprise the following steps: s1: amplifying and displaying the residual focus at the lymphoma position through an electron microscope system, and simultaneously carrying out external sterilization treatment; s2: n element is implanted into lymphoma residual cancer cells at the focus to mark cancer cell DNA. According to the lymphoma tiny residual focus monitoring site screening method and system, the division intensity formula of cancer cells is adopted to calculate the division intensity of the cancer cells in different patients, so that the cancer cell division intensity can be rated, and based on the rating, a treatment scheme which is matched with each patient can be designed, so that the patients can be treated by a classification method, the treatment errors are reduced, the treatment effect is improved, and the delayed treatment is prevented from deteriorating.
Description
Technical Field
The invention relates to the technical field of lymphoma focus monitoring, in particular to a method and a system for screening a monitoring site of a lymphoma tiny residual focus.
Background
The micro residual focus (MRD) refers to the state of micro tumor cells remained in a body after malignant tumor treatment, is a main reason of tumor recurrence, the level of the MRD is generally lower, the traditional imaging (including PET/CT) or laboratory methods cannot find out, a small amount of malignant cells which cannot be detected by the traditional methods can be identified through high-sensitivity detection means such as flow cytometry, quantitative PCR, second-generation sequencing (NGS) and the like, compared with the traditional imaging means, the MRD detection can be used for detecting whether cancer cells have recurrence and metastasis more timely, the MRD detection method has advantages in detection sense, the MRD detection method gradually becomes one of prediction indexes for judging curative effect and prognosis, the indexes mainly comprise ctDNA, CTCs, serology tumor markers and the like, wherein the ctDNA-MRD detection strategy based on ctDNA mutation mainly comprises tumor informed analysis and tumor unaware analysis, the tumor analysis method has the advantages of high sensitivity, good compatibility, multiple effective sites and the like, and the MRD detection method is used for detecting tumor sites in a whole-tumor group according to the whole-sequence analysis.
Patent publication No. CN 115954052B discloses a screening method and a screening system for monitoring sites of tiny residual lesions of solid tumors, wherein the method comprises the following steps: performing mutation detection and mutation filtering treatment on the original data of the tumor sample and the normal tissue sample of the tumor sample by using a full exon sequencing detection mutation method to obtain a primary somatic mutation site; carrying out cloning classification analysis on the primary somatic mutation sites to obtain classified somatic mutation site information; and grading and screening the primary somatic mutation sites based on the classified somatic mutation site information to obtain final somatic mutation sites. The system comprises: the device comprises a detection module, a classification module and a screening module. Through above-mentioned patent, can be through screening somatic mutation site information and then improve the monitoring effect of tiny residual focus, but be inconvenient for carrying out periodic monitoring to cancer cell's division intensity to just also be inconvenient for carrying out different treatments to different patients, influence treatment effect, there is certain defect.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a method and a system for screening a monitoring site of a tiny residual focus of lymphoma, which solve the problems in the prior art.
In order to achieve the above purpose, the invention is realized by the following technical scheme: a lymphoma tiny residual focus monitoring site screening method comprises the following steps:
s1: amplifying and displaying the residual focus at the lymphoma position through an electron microscope system, and simultaneously carrying out external sterilization treatment;
s2: n element is implanted into lymphoma residual cancer cells at focus to mark cancer cell DNA, and the distribution position and number of the cancer cells are accurately detected and recorded through an electron microscope system and a mark visualization system during marking, and the number of the original lymphoma residual cancer cells is marked as T KS The distribution area of the residual cancer cells of the original lymphoma is marked as R KS Storing the data in the form of a physical diagram containing a table to a data terminal;
s3: at the end of the first division period of cancer cells, the lymphoma residual cancer cells at the focus are put into an electron microscope system and a marker development system again for identification and recording, and the number of the cancer cells after division is obtained and recorded as T S1 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S1 ；
S4: at the end of the second division cycle of cancer cells, the procedure in S3 was repeated to obtain the number of cancer cells after the second division and designated as T S2 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S2 ；
S5: the division intensity formula of cancer cells is as follows:
Q X =T SX /T KS (SX is S1 or S2, Q X Is the splitting speed);
F B =R SX /R KS (SX is S1 or S2, F B Is the degree of split range variation);
P KS =（T SX -T KS ）/（R SX -R KS ) (SX is S1 or S2, P KS A quantity range variation ratio);
s6: the intensity level of cancer cell division is calculated according to the formula in S5, and the intensity level of cancer cell classification is as follows:
first-order: q (Q) X Greater than 1.8, F B When the number of the cell lines is smaller than 1.8 and larger than 1.2, the division speed of the cancer cells is high, and the division range is concentrated;
and (2) second-stage: q (Q) X Greater than 1.8, F B When the number of the total cell is more than 1.8, the division speed of the cancer cells is high, and the division range is large;
three stages: q (Q) X Greater than 1.5, F B When the ratio is more than 1.8, the division speed of cancer cells is slow, and the division range is large;
four stages: q (Q) X Less than 1.5, F B When the number of the cell lines is less than 1.8, the division speed of cancer cells is slow, and the division range is concentrated;
s7: according to the grading, the residual cancer cells are classified and monitored, so that a cancer cell chemotherapy cleaning cycle of the unnecessary cancer cells in the patient can be obtained, the division intensity of the cancer cells in different patients can be calculated by adopting a division intensity formula of the cancer cells, so that the grading can be carried out according to the division intensity of the cancer cells, a treatment scheme which is fit for each patient can be designed based on the grading, the patients can be treated by a classification method, the treatment errors are reduced, the treatment effect is improved, the delayed treatment is prevented from deteriorating, the characteristics of the cancer cells can be comprehensively analyzed by synchronously identifying and calculating the number and the range of the cancer cells, the division capacity of the cancer cells is considered, the diffusion range of the cancer cells is considered, and the treatment effect on the patients can be improved.
Q in the S5 X When the value of (2) is 1.+ -. 0.1, it means that the diffusion rate of the residual cancer cell division in the lesion is stopped or slow, and Q is performed multiple times X Detecting the value, Q for a plurality of periods X Still at 1.+ -. 0.1, this indicates that the residual cancer cells have lost their original activity.
The R is KS 、R S1 And R is S2 The calculation is carried out by using the cancer cells marked at the most edge, and the specific calculation method is as follows:
firstly, acquiring a real plane image of cancer cells, and amplifying the image by using an amplifying microscopic device;
secondly, adopting drawing software to connect all cancer cells at the edge;
and thirdly, carrying out modeling calculation on the connecting line area to obtain the specific area of the connecting line area, and then carrying out next rating calculation.
A screening system for a method for screening a monitoring site of a minimal residual lesion of lymphoma, comprising:
the identification module is composed of an electron microscope system and a marker display system, wherein the electron microscope system is used for displaying lymphoma cancer cells in an enlarged mode, and the marker display system is used for displaying cancer cells marked specially;
the processing module comprises a quantity processing unit and an image processing unit, wherein the quantity processing unit is used for calculating the quantity of cancer cells, and the image processing unit is used for calculating the diffusion area range of the cancer cells.
The processing module is internally provided with a data conversion unit, and the data conversion unit is used for digitally converting the distribution positions and the number of the cancer cells and storing the data into a data terminal in a form of a physical chart containing a table.
And a comparison unit is further arranged in the processing module and used for calculating and comparing cancer cells before and after division, so that corresponding data are obtained.
And in the second step, the line connection operation is performed by adopting a line body with the size not more than one micron, meanwhile, the line body is subjected to striking identification by adopting red, and after the line connection is completed, the identification software is adopted to carry out the identification of the specific color, so as to obtain the line connection area.
The login port and the query port of the data terminal are both provided with encryption units, and a chaining system is arranged in the data terminal to automatically encrypt and compress data to below 1KB and transmit the data to a blockchain, so that the data loss is avoided
The invention provides a method and a system for screening monitoring sites of tiny residual focus of lymphoma. The beneficial effects are as follows:
according to the lymphoma tiny residual focus monitoring site screening method and system, the division intensity formula of cancer cells is adopted to calculate the division intensity of the cancer cells in different patients, so that the cancer cell division intensity can be rated, and based on the rating, a treatment scheme which is matched with each patient can be designed, so that the patients can be treated by a classification method, the treatment errors are reduced, the treatment effect is improved, and the delayed treatment is prevented from deteriorating.
According to the lymphoma tiny residual focus monitoring site screening method and system, the number and the range of cancer cells are synchronously identified and calculated, so that comprehensive analysis can be performed on the characteristics of the cancer cells, the division capacity of the cancer cells is considered, the diffusion range of the cancer cells is considered, and the treatment effect on patients can be improved.
Drawings
Fig. 1 is an overall block diagram of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
The embodiment provides a method for screening a monitoring site of a minimal residual focus of lymphoma, which comprises the following steps:
s1: amplifying and displaying the residual focus at the lymphoma position through an electron microscope system, and simultaneously carrying out external sterilization treatment;
s2: n element is implanted into lymphoma residual cancer cells at focus to mark cancer cell DNA, and the distribution position and number of the cancer cells are accurately detected and recorded through an electron microscope system and a mark visualization system during marking, and the number of the original lymphoma residual cancer cells is marked as T KS The distribution area of the residual cancer cells of the original lymphoma is marked as R KS Storing the data in the form of a physical diagram containing a table to a data terminal;
s3: at the end of the first division period of cancer cells, the lymphoma residual cancer cells at the focus are put into an electron microscope system and a marker development system again for identification and recording, and the number of the cancer cells after division is obtained and recorded as T S1 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S1 ；
S4: at the end of the second division cycle of cancer cells, the procedure in S3 was repeated to obtain the number of cancer cells after the second division and designated as T S2 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S2 ；
S5: the division intensity formula of cancer cells is as follows:
Q X =T SX /T KS (SX is S1 or S2, Q X Is the splitting speed);
F B =R SX /R KS (SX is S1 or S2, F B Is the degree of split range variation);
P KS =（T SX -T KS ）/（R SX -R KS ) (SX is S1 or S2, P KS A quantity range variation ratio);
s6: the intensity level of cancer cell division is calculated according to the formula in S5, and the intensity level of cancer cell classification is as follows:
first-order: q (Q) X Greater than 1.8, F B When the number of the cell lines is smaller than 1.8 and larger than 1.2, the division speed of the cancer cells is high, and the division range is concentrated;
and (2) second-stage: q (Q) X Greater than 1.8, F B When the number of the total cell is more than 1.8, the division speed of the cancer cells is high, and the division range is large;
three stages: q (Q) X Greater than 1.5, F B When the ratio is more than 1.8, the division speed of cancer cells is slow, and the division range is large;
four stages: q (Q) X Less than 1.5, F B When the number of the cell lines is less than 1.8, the division speed of cancer cells is slow, and the division range is concentrated;
s7: and carrying out classification monitoring on the residual cancer cells according to the evaluation level, thereby obtaining the chemotherapy cleaning cycle of the cancer cells which are unnecessary and can not be eradicated in the patient.
Q in the S5 X When the value of (2) is 1.+ -. 0.1, it means that the diffusion rate of the residual cancer cell division in the lesion is stopped or slow, and Q is performed multiple times X Detecting the value, Q for a plurality of periods X Still at 1.+ -. 0.1, this indicates that the residual cancer cells have lost their original activity.
The R is KS 、R S1 And R is S2 The calculation is carried out by using the cancer cells marked at the most edge, and the specific calculation method is as follows:
firstly, acquiring a real plane image of cancer cells, and amplifying the image by using an amplifying microscopic device;
secondly, adopting drawing software to connect all cancer cells at the edge;
thirdly, modeling calculation is carried out on the connecting line area to obtain the specific area of the connecting line area, then next grading calculation is carried out, the dividing intensity of cancer cells in different patients is calculated by adopting a dividing intensity formula of the cancer cells, so that grading can be carried out according to the dividing intensity of the cancer cells, a treatment scheme which is fit for each patient can be designed based on the grading, the patients can be treated by a classification method, treatment errors are reduced, treatment effects are improved, deterioration of delay treatment is prevented, comprehensive analysis can be carried out according to the characteristics of the cancer cells by synchronously identifying and calculating the number and the range of the cancer cells, the dividing capacity of the cancer cells is considered, the diffusion range of the cancer cells is considered, and the treatment effect on the patients can be improved.
Example 2
Referring to fig. 1, the present embodiment provides a screening system for a screening method of monitoring a lesion site with minimal residual lymphoma, comprising:
the identification module is composed of an electron microscope system and a marker display system, wherein the electron microscope system is used for displaying lymphoma cancer cells in an enlarged mode, and the marker display system is used for displaying cancer cells marked specially;
the processing module comprises a quantity processing unit and an image processing unit, wherein the quantity processing unit is used for calculating the quantity of cancer cells, and the image processing unit is used for calculating the diffusion area range of the cancer cells.
The processing module is internally provided with a data conversion unit, and the data conversion unit is used for digitally converting the distribution positions and the number of the cancer cells and storing the data into a data terminal in a form of a physical chart containing a table.
And a comparison unit is further arranged in the processing module and used for calculating and comparing cancer cells before and after division, so that corresponding data are obtained.
And in the second step, the line connection operation is performed by adopting a line body with the size not more than one micron, meanwhile, the line body is subjected to striking identification by adopting red, and after the line connection is completed, the identification software is adopted to carry out the identification of the specific color, so as to obtain the line connection area.
The login port and the query port of the data terminal are both provided with encryption units, and a chaining system is arranged in the data terminal to automatically encrypt and compress data to below 1KB and transmit the data to a blockchain, so that the data loss is avoided
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A method for screening a monitoring site of a lymphoma tiny residual focus is characterized by comprising the following steps: the method comprises the following steps:
s1: amplifying and displaying the residual focus at the lymphoma position through an electron microscope system, and simultaneously carrying out external sterilization treatment;
s2: n element is implanted into lymphoma residual cancer cells at focus to mark cancer cell DNA, and the distribution position and number of the cancer cells are accurately detected and recorded through an electron microscope system and a mark visualization system during marking, and the number of the original lymphoma residual cancer cells is marked as T KS Residual carcinoma of original lymphomaThe area of the distribution range of the cells is denoted as R KS Storing the data in the form of a physical diagram containing a table to a data terminal;
s3: at the end of the first division period of cancer cells, the lymphoma residual cancer cells at the focus are put into an electron microscope system and a marker development system again for identification and recording, and the number of the cancer cells after division is obtained and recorded as T S1 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S1 ；
S4: at the end of the second division cycle of cancer cells, the procedure in S3 was repeated to obtain the number of cancer cells after the second division and designated as T S2 Meanwhile, the distribution area of the residual cancer cells of the original lymphoma is recorded as R S2 ；
S5: the division intensity formula of cancer cells is as follows:
Q X =T SX /T KS (SX is S1 or S2, Q X Is the splitting speed);
F B =R SX /R KS (SX is S1 or S2, F B Is the degree of split range variation);
P KS =（T SX -T KS ）/（R SX -R KS ) (SX is S1 or S2, P KS A quantity range variation ratio);
s6: the intensity level of cancer cell division is calculated according to the formula in S5, and the intensity level of cancer cell classification is as follows:
first-order: q (Q) X Greater than 1.8, F B When the number of the cell lines is smaller than 1.8 and larger than 1.2, the division speed of the cancer cells is high, and the division range is concentrated;
and (2) second-stage: q (Q) X Greater than 1.8, F B When the number of the total cell is more than 1.8, the division speed of the cancer cells is high, and the division range is large;
three stages: q (Q) X Greater than 1.5, F B When the ratio is more than 1.8, the division speed of cancer cells is slow, and the division range is large;
four stages: q (Q) X Less than 1.5, F B When the number of the cell lines is less than 1.8, the division speed of cancer cells is slow, and the division range is concentrated;
s7: and carrying out classification monitoring on the residual cancer cells according to the evaluation level, thereby obtaining the chemotherapy cleaning cycle of the cancer cells which are unnecessary and can not be eradicated in the patient.
2. The method for screening a monitoring site for a minimal residual disease of lymphoma according to claim 1, wherein the method comprises the steps of: q in the S5 X When the value of (2) is 1.+ -. 0.1, it means that the diffusion rate of the residual cancer cell division in the lesion is stopped or slow, and Q is performed multiple times X Detecting the value, Q for a plurality of periods X Still at 1.+ -. 0.1, this indicates that the residual cancer cells have lost their original activity.
3. The method for screening a monitoring site for a minimal residual disease of lymphoma according to claim 2, wherein the method comprises the steps of: the R is KS 、R S1 And R is S2 The calculation is carried out by using the cancer cells marked at the most edge, and the specific calculation method is as follows:
firstly, acquiring a real plane image of cancer cells, and amplifying the image by using an amplifying microscopic device;
secondly, adopting drawing software to connect all cancer cells at the edge;
and thirdly, carrying out modeling calculation on the connecting line area to obtain the specific area of the connecting line area, and then carrying out next rating calculation.
4. A screening system for use in a method for screening a minimal residual disease focus for lymphoma according to any one of claims 1-3, wherein: comprising the following steps:
the identification module is composed of an electron microscope system and a marker display system, wherein the electron microscope system is used for displaying lymphoma cancer cells in an enlarged mode, and the marker display system is used for displaying cancer cells marked specially;
the processing module comprises a quantity processing unit and an image processing unit, wherein the quantity processing unit is used for calculating the quantity of cancer cells, and the image processing unit is used for calculating the diffusion area range of the cancer cells.
5. The screening system for a method for screening a monitoring site for a minimal residual disease of lymphoma according to claim 4, wherein: the processing module is internally provided with a data conversion unit, and the data conversion unit is used for digitally converting the distribution positions and the number of the cancer cells and storing the data into a data terminal in a form of a physical chart containing a table.
6. The screening system for the lymphoma minimal residual disease monitoring site screening method according to claim 5, wherein: and a comparison unit is further arranged in the processing module and used for calculating and comparing cancer cells before and after division, so that corresponding data are obtained.
7. A screening system for a method of screening a minimal residual disease lymphoma according to claim 3, wherein: and in the second step, the line connection operation is performed by adopting a line body with the size not more than one micron, meanwhile, the line body is subjected to striking identification by adopting red, and after the line connection is completed, the identification software is adopted to carry out the identification of the specific color, so as to obtain the line connection area.
8. The screening system for the lymphoma minimal residual disease monitoring site screening method according to claim 5, wherein: the login port and the query port of the data terminal are both provided with encryption units, and a chaining system is arranged in the data terminal to automatically encrypt and compress data to below 1KB and transmit the data to a blockchain, so that data loss is avoided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311082157.9A CN117153251A (en) | 2023-08-26 | 2023-08-26 | Method and system for screening monitoring sites of lymphoma tiny residual focus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311082157.9A CN117153251A (en) | 2023-08-26 | 2023-08-26 | Method and system for screening monitoring sites of lymphoma tiny residual focus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117153251A true CN117153251A (en) | 2023-12-01 |
Family
ID=88886009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311082157.9A Pending CN117153251A (en) | 2023-08-26 | 2023-08-26 | Method and system for screening monitoring sites of lymphoma tiny residual focus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117153251A (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002218995A (en) * | 2000-11-22 | 2002-08-06 | Masahito Taya | Method, apparatus and program for evaluating cell proliferation potency |
| JP2004344049A (en) * | 2003-05-21 | 2004-12-09 | Masahito Taya | Apparatus for evaluating cell growth ability and method therefor |
| US20070292901A1 (en) * | 2006-06-15 | 2007-12-20 | Costello Penelope C | Methods and kits for evaluating and measuring the oncological status of tissue samples in three-dimensional physiological matrices |
| WO2009157530A1 (en) * | 2008-06-26 | 2009-12-30 | 株式会社ニコン | Embryo-monitoring apparatus |
| WO2011023363A1 (en) * | 2009-08-25 | 2011-03-03 | Universität Rostock | Method and device for cell sample diagnosis |
| CN102220416A (en) * | 2011-04-20 | 2011-10-19 | 北京师范大学 | Method for monitoring number of cell division, and application thereof |
| JP2013169291A (en) * | 2012-02-20 | 2013-09-02 | Kao Corp | Simulation apparatus and simulation method for epidermal tissues |
| US20150284688A1 (en) * | 2012-11-09 | 2015-10-08 | Marco Archetti | Diffusible factors and cancer cells |
| US20190266723A1 (en) * | 2016-09-29 | 2019-08-29 | Animantis, Llc | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
| CA3164113A1 (en) * | 2019-12-09 | 2021-06-17 | Kromatid, Inc. | Methods for high resolution spectral chromosome banding to detect chromosomal abnormalities |
| WO2022216778A1 (en) * | 2021-04-06 | 2022-10-13 | Berkeley Lights, Inc. | Methods of microfluidic assay and bioproduction from non-mammalian cells and kits therefor |
| CN115954052A (en) * | 2023-03-15 | 2023-04-11 | 广州迈景基因医学科技有限公司 | Method and system for screening monitoring sites of tiny residual lesions of solid tumors |
| WO2023102501A1 (en) * | 2021-12-01 | 2023-06-08 | Kromatid, Inc. | METHODS FOR ANALYZING CHROMOSOMES AND CHROMOSOMAL ABNORMALITIES USING dGH WITH FLUORESCENCE SORTING AND/OR ARRAYS |
-
2023
- 2023-08-26 CN CN202311082157.9A patent/CN117153251A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002218995A (en) * | 2000-11-22 | 2002-08-06 | Masahito Taya | Method, apparatus and program for evaluating cell proliferation potency |
| JP2004344049A (en) * | 2003-05-21 | 2004-12-09 | Masahito Taya | Apparatus for evaluating cell growth ability and method therefor |
| US20070292901A1 (en) * | 2006-06-15 | 2007-12-20 | Costello Penelope C | Methods and kits for evaluating and measuring the oncological status of tissue samples in three-dimensional physiological matrices |
| WO2009157530A1 (en) * | 2008-06-26 | 2009-12-30 | 株式会社ニコン | Embryo-monitoring apparatus |
| WO2011023363A1 (en) * | 2009-08-25 | 2011-03-03 | Universität Rostock | Method and device for cell sample diagnosis |
| CN102220416A (en) * | 2011-04-20 | 2011-10-19 | 北京师范大学 | Method for monitoring number of cell division, and application thereof |
| JP2013169291A (en) * | 2012-02-20 | 2013-09-02 | Kao Corp | Simulation apparatus and simulation method for epidermal tissues |
| US20150284688A1 (en) * | 2012-11-09 | 2015-10-08 | Marco Archetti | Diffusible factors and cancer cells |
| US20190266723A1 (en) * | 2016-09-29 | 2019-08-29 | Animantis, Llc | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
| CA3164113A1 (en) * | 2019-12-09 | 2021-06-17 | Kromatid, Inc. | Methods for high resolution spectral chromosome banding to detect chromosomal abnormalities |
| WO2022216778A1 (en) * | 2021-04-06 | 2022-10-13 | Berkeley Lights, Inc. | Methods of microfluidic assay and bioproduction from non-mammalian cells and kits therefor |
| WO2023102501A1 (en) * | 2021-12-01 | 2023-06-08 | Kromatid, Inc. | METHODS FOR ANALYZING CHROMOSOMES AND CHROMOSOMAL ABNORMALITIES USING dGH WITH FLUORESCENCE SORTING AND/OR ARRAYS |
| CN115954052A (en) * | 2023-03-15 | 2023-04-11 | 广州迈景基因医学科技有限公司 | Method and system for screening monitoring sites of tiny residual lesions of solid tumors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lindberg et al. | Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins | |
| Agbor-Enoh et al. | Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation | |
| Kluk et al. | MYC immunohistochemistry to identify MYC-driven B-cell lymphomas in clinical practice | |
| CN112805563A (en) | Cell-free DNA for assessing and/or treating cancer | |
| US20070178503A1 (en) | In-situ genomic DNA chip for detection of cancer | |
| CN109124660B (en) | Gastrointestinal stromal tumor postoperative risk detection method and system based on deep learning | |
| Lazcano‐Ponce et al. | Specimen self‐collection and HPV DNA screening in a pilot study of 100,242 women | |
| WO2018054254A1 (en) | Method and system for identifying tumor load in sample | |
| Roh | The utilization of cytologic and small biopsy samples for ancillary molecular testing | |
| Adam et al. | Chronic antibody-mediated rejection in nonhuman primate renal allografts: validation of human histological and molecular phenotypes | |
| CN112768000B (en) | Method and device for predicting MET gene copy number change type | |
| Pajor et al. | State‐of‐the‐art FISHing: Automated analysis of cytogenetic aberrations in interphase nuclei | |
| CN113257360B (en) | Cancer screening model, and construction method and construction device of cancer screening model | |
| CN104212889A (en) | Probe set for diagnosing Xp11.2 ectopic perivascular epithelioid cell neoplasm and application of probe set | |
| TW201837185A (en) | Non-invasive detection and recurrence monitoring method for bladder cancer | |
| US20200109457A1 (en) | Chromosomal assessment to diagnose urogenital malignancy in dogs | |
| CN113674803A (en) | Detection method of copy number variation and application thereof | |
| CN110592208B (en) | Capture probe composition of three subtypes of thalassemia as well as application method and application device thereof | |
| US20180040120A1 (en) | Methods for quantitative assessment of mononuclear cells in muscle tissue sections | |
| CN107567631A (en) | Tissue sample analysis technology | |
| Rygiel et al. | Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population | |
| Theodosiou et al. | Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases | |
| Pajor et al. | Automated signal pattern evaluation of a bladder cancer specific multiprobe‐fish assay applying a user‐trainable workstation | |
| Korn et al. | Objective method of comparing DNA microarray image analysis systems | |
| CN117153251A (en) | Method and system for screening monitoring sites of lymphoma tiny residual focus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |